Home > Compound List > Product Information
Ibandronate_Molecular_structure_CAS_114084-78-5)
Click picture or here to close

Ibandronate

Catalog No. DB00710 Name DrugBank
CAS Number 114084-78-5 Website http://www.ualberta.ca/
M. F. C9H23NO7P2 Telephone (780) 492-3111
M. W. 319.228942 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 591

SYNONYMS

IUPAC name
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
IUPAC Traditional name
ibandronate
Brand Name
Boniva
Bonviva
Bondronat
Synonyms
ibandronate
Ibandronate sodium monohydrate
R484
Ibandronic Acid
Ibandronate sodium

DATABASE IDS

PubChem CID 60852
PubChem SID 46508134
CAS Number 114084-78-5

PROPERTIES

Hydrophobicity(logP) -2.1
Solubility Freely soluble

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Indication For the treatment and prevention of osteoporosis in postmenopausal women.
Pharmacology Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Toxicity LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
Affected Organisms
Humans and other mammals
Biotransformation No evidence of ibandronate being metabolized in humans.
Absorption Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Half Life 10-60 hours
Protein Binding 90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
Elimination Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
Distribution * 90 L
Clearance * 84 to 160 mL/min [IV administration]
References
Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. Pubmed